Header Logo

Connection

Joan Lo to Osteoporosis

This is a "connection" page, showing publications Joan Lo has written about Osteoporosis.
Connection Strength

6.177
  1. Changing trends in bisphosphonate therapy: a twenty-five-year surveillance in a single US integrated healthcare system. Osteoporos Int. 2025 Apr; 36(4):741-747.
    View in: PubMed
    Score: 0.904
  2. Challenges of fracture risk assessment in Asian and Black women. Am J Manag Care. 2024 Mar; 30(3):140-144.
    View in: PubMed
    Score: 0.847
  3. Osteoporosis and Fracture Risk among Older US Asian Adults. Curr Osteoporos Rep. 2023 10; 21(5):592-608.
    View in: PubMed
    Score: 0.814
  4. The Epidemiology of Metatarsal Fractures Among Older Females With Bisphosphonate Exposure. J Foot Ankle Surg. 2020 Mar - Apr; 59(2):269-273.
    View in: PubMed
    Score: 0.642
  5. Vitamin D Status Among Older Women Initiating Osteoporosis Therapy. J Am Geriatr Soc. 2019 10; 67(10):2207-2208.
    View in: PubMed
    Score: 0.619
  6. Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy. Breast Cancer Res Treat. 2018 Apr; 168(2):523-530.
    View in: PubMed
    Score: 0.551
  7. Applying ethnic-specific bone mineral density T-scores to Chinese women in the USA. Osteoporos Int. 2016 12; 27(12):3477-3484.
    View in: PubMed
    Score: 0.501
  8. Oral health considerations in older women receiving oral bisphosphonate therapy. J Am Geriatr Soc. 2011 May; 59(5):916-22.
    View in: PubMed
    Score: 0.348
  9. How Should We Counsel Asian Americans about Fracture Risk? J Am Geriatr Soc. 2020 07; 68(7):1613-1614.
    View in: PubMed
    Score: 0.163
  10. Determinants of Oral Bisphosphonate Use Beyond 5 Years. J Manag Care Spec Pharm. 2020 Feb; 26(2):197-202.
    View in: PubMed
    Score: 0.160
  11. Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study. Breast Cancer Res Treat. 2020 Feb; 180(1):187-195.
    View in: PubMed
    Score: 0.159
  12. Using Pharmacy Data and Adherence to Define Long-Term Bisphosphonate Exposure in Women. J Manag Care Spec Pharm. 2019 Jun; 25(6):719-723.
    View in: PubMed
    Score: 0.152
  13. Bone health history in breast cancer patients on aromatase inhibitors. PLoS One. 2014; 9(10):e111477.
    View in: PubMed
    Score: 0.111
  14. Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes. J Oral Maxillofac Surg. 2012 Aug; 70(8):1844-53.
    View in: PubMed
    Score: 0.094
  15. The definition of atypical femoral fractures should include periprosthetic femoral fractures (PAFFs). Osteoporos Int. 2025 Mar; 36(3):539-546.
    View in: PubMed
    Score: 0.057
  16. Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis. Breast Cancer Res Treat. 2017 02; 161(3):501-513.
    View in: PubMed
    Score: 0.032
  17. Application of new method for evaluating performance of fracture risk tool. Am J Manag Care. 2012 Oct 01; 18(10):e398.
    View in: PubMed
    Score: 0.024

© 2025 Kaiser Permanente